Format

Send to

Choose Destination
Nature. 2019 Feb;566(7745):E11-E12. doi: 10.1038/s41586-019-0974-0.

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Author information

1
Memorial Sloan Kettering Cancer Center, New York, New York, USA. hymand@mskcc.org.
2
University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
3
Memorial Sloan Kettering Cancer Center, New York, New York, USA.
4
Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
5
Dana-Faber Cancer Institute, Boston, Massachusetts, USA.
6
Massachusetts Hospital Cancer Center, Boston, Massachusetts, USA.
7
USC Norris Comprehensive Cancer Center, Los Angeles, California, USA.
8
START Madrid Fundación Jímenez Díaz, Madrid, Spain.
9
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
10
START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain.
11
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
12
Washington University in St. Louis School of Medicine, St Louis, Missouri, USA.
13
Puma Biotechnology Inc., Los Angeles, California, USA.

Abstract

The 'Competing interests' statement of this Article has been updated; please see the accompanying Amendment. The original Article has not been corrected online.

PMID:
30755741
DOI:
10.1038/s41586-019-0974-0

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center